Summary
Vertex Pharmaceuticals Inc. (VRTX) reported strong revenue growth in 2021, driven by the continued success of its cystic fibrosis (CF) treatments, particularly TRIKAFTA/KAFTRIO. The company achieved a 22% increase in net product revenues, reaching $7.57 billion, fueled by international expansion of KAFTRIO and the expanded indication for TRIKAFTA in younger children in the U.S. Vertex is actively expanding its CF portfolio with a new triple combination therapy in Phase 3 trials and pursuing gene-editing approaches for the remaining CF patient population. Beyond CF, Vertex is making significant progress across a diversified pipeline targeting serious diseases such as sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, and pain. Key developments include advancing CTX001 (CRISPR gene-editing therapy) towards regulatory submissions for sickle cell disease and beta thalassemia, and positive early data for VX-880, a cell therapy for type 1 diabetes. The company's strong financial position, with $7.5 billion in cash, cash equivalents, and marketable securities, supports its ongoing investment in research and development and strategic collaborations.
Financial Highlights
51 data points| Revenue | $7.57B |
| Cost of Revenue | $904.20M |
| Gross Profit | $6.67B |
| R&D Expenses | $3.05B |
| SG&A Expenses | $840.10M |
| Operating Expenses | $4.79B |
| Operating Income | $2.78B |
| Net Income | $2.34B |
| EPS (Basic) | $9.09 |
| EPS (Diluted) | $9.01 |
| Shares Outstanding (Basic) | 257.70M |
| Shares Outstanding (Diluted) | 259.90M |
Key Highlights
- 1Net product revenues increased by 22% to $7.57 billion in 2021, primarily driven by the strong performance and international expansion of TRIKAFTA/KAFTRIO for cystic fibrosis (CF).
- 2The company advanced its CF pipeline, initiating Phase 3 trials for a new triple combination therapy (VX-121/tezacaftor/VX-561) and is progressing mRNA therapeutics for CF patients not served by small molecules.
- 3Vertex made significant strides in its non-CF pipeline, with CTX001 (CRISPR gene-editing therapy for sickle cell disease and beta thalassemia) anticipated for regulatory submissions in late 2022.
- 4Positive Phase 1/2 data was announced for VX-880, a stem cell-derived therapy for type 1 diabetes, with continued patient dosing planned for 2022.
- 5VX-147 showed positive Phase 2 results for APOL1-mediated kidney disease, with pivotal development expected to begin in Q1 2022.
- 6Research and development expenses increased significantly to $3.05 billion in 2021, largely due to a $900 million upfront payment to CRISPR Therapeutics for the CTX001 collaboration.
- 7Vertex ended 2021 with a robust cash position of $7.5 billion, providing ample resources for ongoing research, development, and business development activities.